14 C "synth to clinic" simplifies development process, says Quotient CEO

14 C "synth to clinic" simplifies development process, says Quotient CEO

5 Minuten

Beschreibung

vor 16 Jahren
UK contract services firm Quotient Bioresearch says its
"Synthesis-to-clinic" service for 14 C labelled compounds can
simplify early drug development.

Kommentare (0)

Lade Inhalte...

Abonnenten

15
15